GNBT
GNBT is not just Bird Flu:
Generex Biotechnology Granted United States Patent in Connection With Its RapidMist(TM) Device
Thursday January 5, 9:00 am ET
New Patent Expands Protection for RapidMist
TORONTO--(MARKET WIRE)--Jan 5, 2006 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News), a leader in the area of buccal drug delivery, announced today that it has been granted another United States patent. The patent entitled, "Cleaning Compounds for and Method of Cleaning Valves and Actuators of Metered Dose Dispensers Containing Pharmaceutical Compositions," relates to the formulation and methodology for cleaning the Company's proprietary RapidMist device which is designed to deliver pharmaceutical products, including Oral-lyn(TM), the Company's proprietary oral insulin product, into the buccal cavity (the mouth) where it is absorbed into the bloodstream.
ADVERTISEMENT
The patent covers a method of cleaning the RapidMist metered dose spray device, and a cleaning composition for such cleaning, to prevent the device from becoming clogged with medication. The cleaning composition is non-toxic and will not harm the user of the device following cleaning. This process makes the RapidMist device suitable for long-term, chronic use and ensures the accuracy and efficacy of the metered medication doses.
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.
For more information, visit the Generex Web site at www.generex.com. |
